Conference Call with Natco Pharma Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Natco Pharma declares Q4FY22 result: NATCO Pharma has recorded consolidated total revenue of INR 2043.8 Crore for the year ended on 31st March, 2022, as against INR 2155.7 Crore for the last year. The net profit for the period, on a consolidated basis, was INR 170.0 Crore, as against INR 442.4 Crore last year. The reduction in the profit was primarily due to inventory value write-off and provision of receivables related to Covid products, with inventory value write-off of INR 232.0 Crore and provision of INR 46.0 Crore towards estimated credit loss. Export business performed well during the quarter driven by Lenalidomide sales and profit. For the fourth quarter (Q4) ended March 31st, 2022, the company recorded net revenue of INR 610.6 Crore, on a consolidated basis, as against INR 359.7 Crore during Q4, FY 2021. There was a loss for the fourth quarter period, on a consolidated basis, of INR 50.5 Crore, primarily due to inventory value write-off and provision of estimated credit losses, as against a profit of INR 53.0 Crore same quarter last year. Result PDF
Conference Call with Natco Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.